Silence Therapeutics PLC

Silence Therapeutics accelerating into the clinic

David Solomon, chief executive of Silence Therapeutics PLC (LON:SLN), updates Proactive London's Andrew Scott on the progress of its lead candidate SLN124  which is being developed to treat iron overload disorders.

It already has orphan drug designation in Europe and a phase Ib, first-in-human trial is scheduled to start in the third quarter.

Solomon also elaborates on two other exciting assets in the portfolio - one of them being SLN360 which is being developed as a potential treatment for cardiovascular disease.

Quick facts: Silence Therapeutics PLC

Price: £2.06

Market: AIM
Market Cap: £160.5 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...



Silence Therapeutics 'in a hot space with few competitors'

Silence Therapeutics' (LON:SLN) executive chair Annalisa Jenkins sat down with Proactive's Andrew Scott to discuss her strategy for taking the drug developer forward and the 'exciting opportunities' in the RNAi space. On what attracted Jenkins to join Silence, she says: ''The opportunity...

on 12/6/18


Additional Listing

1 day, 10 hours ago

Notice of Results and R&D day

5 days, 18 hours ago

Additional Listing

1 week, 1 day ago

Additional Listing

1 week, 5 days ago

Additional Listing

2 weeks ago

Additional Listing

2 weeks, 1 day ago

Holding(s) in Company

2 weeks, 5 days ago

2 min read